Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Digest.
Press releases published on March 11, 2025
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
GlobeNewswire
·
March 11, 2025
DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while …
FBD Token: Bridging Real World Asset and Blockchain Innovation
GlobeNewswire
·
March 11, 2025
DUBAI, United Arab Emirates, March 11, 2025 (GLOBE NEWSWIRE) -- Blockchain is no longer just about cryptocurrencies—it’s transforming industries worldwide. With its power to manage assets securely through smart contracts and decentralized finance (DeFi), …
PDS Biotech Leadership to Participate in March Conferences
GlobeNewswire
·
March 11, 2025
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
Integral Metals Announces the Addition of John David Clark as an Advisor to the Company
GlobeNewswire
·
March 11, 2025
CALGARY, Alberta, March 11, 2025 (GLOBE NEWSWIRE) -- Integral Metals Corp. (CSE: INTG | OTC: ITGLF | FSE: ZK9) (the “Company” or “Integral”) is pleased to announce the addition of John David Clark as an Advisor to the Company. With his extensive experience …
Torr Metals Expands Kolos Project with Optioning of Drill-Permitted Bertha Property, Featuring Historical High-Grade Copper Up to 8.48% in Outcrop
GlobeNewswire
·
March 11, 2025
VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) -- via IBN – Torr Metals Inc. (“Torr” or the "Company") (TSX-V: TMET.V) is pleased to announce the signing of an option agreement (the “Option Agreement”), subject to TSX Venture Exchange (“TSXV …
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
GlobeNewswire
·
March 11, 2025
- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation …
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
GlobeNewswire
·
March 11, 2025
Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, …
BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
GlobeNewswire
·
March 11, 2025
Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company …
Gauzy Ltd. Announces Record Fourth Quarter and Full Year 2024 Results
GlobeNewswire
·
March 11, 2025
Delivers Fourth Quarter Revenue Growth of 41.8% Driven by Broad-Based Strength Across All Segments Narrows Adjusted Net Loss for the Quarter, Continuing Path to Improved Profitability Delivers on Goal to Produce First Ever Quarter of Positive Adjusted …
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
GlobeNewswire
·
March 11, 2025
PETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful completion of enrollment in the SHIELD II …
Aya Gold & Silver Announces February 2025 Production Results
GlobeNewswire
·
March 11, 2025
MONTREAL, March 11, 2025 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce production of 357,333 ounces (“oz”) of silver (“Ag”) in February at its Zgounder Silver Mine, located in the …
Aya Or & Argent annonce ses résultats de production pour février 2025
GlobeNewswire
·
March 11, 2025
MONTRÉAL, 11 mars 2025 (GLOBE NEWSWIRE) -- Aya Or & Argent Inc. (TSX : AYA; OTCQX : AYASF) (« Aya » ou la « Société ») a le plaisir d’annoncer une production de 357 333 onces (« oz ») d’argent (« Ag ») en février à sa mine d’argent Zgounder, située dans le …
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
GlobeNewswire
·
March 11, 2025
- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression - VLS-01 is being …
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 11, 2025
Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP- …
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
GlobeNewswire
·
March 11, 2025
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, …
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
GlobeNewswire
·
March 11, 2025
– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival – – Vepdegestrant is the first PROTAC degrader to demonstrate …
Fiverr Announces Board Authorization of Additional $100 Million for Share Repurchase Program
GlobeNewswire
·
March 11, 2025
NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Fiverr International Ltd, (NYSE: FVRR), the company that is changing how the world works together, announced that on March 10, 2025, its Board of Directors has authorized additional repurchases of up to $100 …